Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - fluorouracil - solution for infusion or injection - fluorouracil 50 mg/ml - antineoplastic agents

Malta - English - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - fluorouracil - solution for infusion or injection - fluorouracil 50 mg/ml - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare limited - fluorouracil - solution for injection/infusion - 50 milligram(s)/millilitre - pyrimidine analogues; fluorouracil

Australia - English - Department of Health (Therapeutic Goods Administration)

cvn pharma pty ltd - fluorouracil, quantity: 5 % w/w - cream - excipient ingredients: propylene glycol; polysorbate 60; purified water; stearyl alcohol; methyl hydroxybenzoate; propyl hydroxybenzoate; white soft paraffin - solar and senile keratoses, bowen's disease.

United States - English - NLM (National Library of Medicine)

sandoz inc - fluorouracil (unii: u3p01618rt) (fluorouracil - unii:u3p01618rt) - fluorouracil 50 mg in 1 ml - fluorouracil is effective in the palliative management of carcinoma of the colon, rectum, breast, stomach and pancreas. fluorouracil therapy is contraindicated for patients in a poor nutritional state, those with depressed bone marrow function, those with potentially serious infections or those with a known hypersensitivity to fluorouracil.

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - fluorouracil - solution for injection/infusion - 50 milligram(s)/millilitre - pyrimidine analogues; fluorouracil

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml;   - solution for injection - 1000 mg/20ml - active: fluorouracil 50 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fluorouracil 50 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml;   - solution for injection - 2500 mg/50ml - active: fluorouracil 50 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - fluorouracil 50 mg/ml;   - solution for injection - 500 mg/10ml - active: fluorouracil 50 mg/ml   excipient: hydrochloric acid sodium hydroxide water for injection - alone or in combination, for the palliative treatment of malignant tumours, particularly of the breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine (cervical particularly), ovarian and bladder carcinomas. fluorouracil should only be used when other proven measures have failed or are considered impractical.